Search Results

Pfizer is proud to announce that it is supporting a McMaster University-led study, through the Ontario Clinical Oncology Group, that aims to improve care for Canadians living with multiple myeloma.

Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) today announced encouraging results from it’s completed pre-clinical CHRP study conducted with McMaster University evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for individuals suffering from interstitial lung diseases (ILD).

Fuzionaire Diagnostics, Inc. (“Fuzionaire Dx”) today announced a collaborative research agreement with McMaster University (“McMaster”) under which theranostic radiopharmaceuticals developed with Fuzionaire Dx’s HetSiFA® platform will be evaluated at McMaster’s comprehensive preclinical nuclear medicine facilities.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced it has entered into an additional research project expanding on the ongoing collaboration with McMaster University to develop an inhalable immuno-therapeutic/-prophylactic for COVID-19-induced lung fibrosis.

Today, Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ) and McMaster University (“ McMaster ”) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final installment of the Collaborative Research and Development grant, with a value of $120,000, from the Natural Sciences and Engineering Research Council of Canada (NSERC).

Today, Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ) and McMaster University (“ McMaster ”) are reporting a preliminary, yet significant milestone in the investigation of an orally delivered vaccine candidate for COVID-19.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

More than 700 guests, including employees, community members, elected officials and SC Governor Henry McMaster, celebrated the grand opening of Nutramax Laboratories’ 200,000 square foot expansion.

AMO Pharma Limited announced a collaboration with Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02, AMO Pharma’s investigational oral glycogen synthase kinase 3 beta inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy.